Table 4. Annualized event rates for clinical outcomes in the higher-dose edoxaban, lower-dose edoxaban, and warfarin arms stratified by ABC-stroke and ABC-bleeding risk scores.

			1-year Risk of Bleeding Predicted by ABC-Bleeding Model
			< 1 %			1–2 %			> 2 %
			LDER	HDER	WAR	LDER	HDER	WAR	LDER	HDER	WAR
1-year Risk of S/SEE Predicted by ABC-Stroke Model	<1%	N	175	195	208	390	386	388	269	237	239
		Stroke/SEE	0.43	0.77	0.18	0.38	0.78	0.87	1.26	0.48	1.09
		Bleeding	0.48	0.42	0.59	0.84	1.61	1.89	1.46	2.44	3.50
		NCO	1.43	1.48	1.38	1.67	2.80	2.64	2.44	3.57	4.25
	1–2%	N	18	28	19	307	308	322	884	904	844
		Stroke/SEE	0.00	2.84	2.02	1.11	1.62	0.97	1.91	1.16	1.66
		Bleeding	0.00	0.00	2.19	0.96	1.58	2.18	2.17	3.68	4.05
		NCO	0.00	4.71	2.19	2.35	3.59	4.12	4.86	5.62	5.96
	>2%	N	1	3	3	47	29	52	737	732	739
		Stroke/SEE	0.00	0.00	0.00	2.68	2.77	4.62	3.58	2.92	3.21
		Bleeding	0.00	0.00	0.00	3.14	0.00	0.86	3.85	4.83	5.85
		NCO	0.00	0.00	0.00	4.18	4.91	5.30	9.22	8.31	10.91

The net clinical outcome is a composite of stroke, systemic embolic event, major bleeding, and all-cause mortality. HDER indicates high-dose edoxaban regimen; LDER, low-dose edoxaban regimen; NCO, net clinical outcome; S/SEE, stroke or systemic embolic event; WAR, warfarin.